The impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapy

Basit Öğe Kaydı
dc.contributor.authorYavaş, Güler
dc.contributor.authorYavaş, Çağdaş
dc.contributor.authorÇelik, Esin
dc.contributor.authorŞen, E.
dc.contributor.authorAta, O.
dc.contributor.authorAfşar, Rengin Elsürer
dc.date.accessioned2020-03-26T20:19:30Z
dc.date.available2020-03-26T20:19:30Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: To evaluate impact of spironolactone (S) on pulmonary toxicity of concomitant use of thoracic radiotherapy (RT) and trastuzumab (T). Materials and Methods: Eighty rats were divided into eight groups: group (G) 1 was control group; G2, G3 and G4 were RT, S and T groups; G5, G6, G7 and G8 were RT+T, T+S, RT+S and RT+T+S groups respectively. Rats were sacrificed at 6 hour, 21 and 100 day after RT and lung samples were retrieved. Results: By 100th days of RT inflammation score, lung fibrosis score and TGF- expression were significantly different within study groups (p values were 0.002, 0.001 and 0.043 respectively). Inflammation score of G8 was significantly lower than inflammation scores of G2 and G5 (p values: G2-G8=0.004, and G5-G8=0.022). Inflammation score of G2 was significantly higher than G7 (p=0.028). There were significant differences regarding to fibrosis scores between G2-G8 (p=0.015), G2-G7 (p=0.017) and G5-G8 (p=0.011). TGF-beta expression was higher in both G2 and G5 when compared to G8 (p = 0.038). Conclusion: Our results suggested that S is an effective treatment option for improving radiation-induced pulmonary fibrosis. These findings should be clarified with further preclinical and clinical studies.en_US
dc.description.sponsorshipSelcuk UniversitySelcuk Universityen_US
dc.description.sponsorshipThis work was supported by Selcuk University. There is no role of study sponsors in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript and in the decision to submit the manuscript for publication.en_US
dc.identifier.citationYavas, G., Yavas, C., Celik, E., Sen, E., Ata, O., Afsar, R. E. (2019). The Impact of Spironolactone on the Lung Injury Induced by Concomitant Trastuzumab and Thoracic Radiotherapy. International Journal of Radiation Research, 17(1), 87-95.
dc.identifier.doi10.18869/acadpub.ijrr.17.1.87en_US
dc.identifier.endpage95en_US
dc.identifier.issn2322-3243en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage87en_US
dc.identifier.urihttps://dx.doi.org/10.18869/acadpub.ijrr.17.1.87
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38295
dc.identifier.volume17en_US
dc.identifier.wosWOS:000464529800009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorYavas, G.
dc.institutionauthorYavas, C.
dc.institutionauthorCelik, E.
dc.institutionauthorSen, E.
dc.institutionauthorAta, O.
dc.institutionauthorAfsar, R. E.
dc.language.isoenen_US
dc.publisherIJRR-IRANIAN JOURNAL RADIATION RESen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF RADIATION RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAldosteroneen_US
dc.subjectpulmonary fibrosisen_US
dc.subjectradiotherapyen_US
dc.subjectspironolactoneen_US
dc.subjectTrastuzumaben_US
dc.titleThe impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
G. Yavas.pdf
Boyut:
1.73 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
İç Hastalıkları/Makale Koleksiyonu
Radyasyon Onkolojisi/Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıbbi Pataloji/Makale Koleksiyonu